Introduction

Medical Oncologist Dr. Neal Love met with Dr. Edward Garren from the David Geffen School of Medicine at the University of California, Los Angeles. The first approval was Novolamab in squamous alcarcinoma. Then there was an approval for Pembrolizumab in PDL1 high, greater than 50 percent over previously treated patients across histologies. Before immune checkpoint inhibitors arrived, lung cancer clinics looked quite similar to those today.